Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,437,441
  • Shares Outstanding, K 160,179
  • Annual Sales, $ 441,760 K
  • Annual Income, $ -281,580 K
  • 60-Month Beta 0.74
  • Price/Sales 8.06
  • Price/Cash Flow N/A
  • Price/Book 6.54
Trade ACAD with:

Options Overview

Details
  • Implied Volatility 92.46%
  • Historical Volatility 42.32%
  • IV Percentile 85%
  • IV Rank 52.88%
  • IV High 140.61% on 03/09/21
  • IV Low 38.43% on 06/03/21
  • Put/Call Vol Ratio 11.30
  • Today's Volume 6,396
  • Volume Avg (30-Day) 1,873
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 38,294
  • Open Int (30-Day) 36,556

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.30
  • Number of Estimates 10
  • High Estimate -0.23
  • Low Estimate -0.37
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.32 +0.66%
on 07/23/21
26.32 -18.45%
on 06/25/21
-3.06 (-12.48%)
since 06/23/21
3-Month
19.20 +11.77%
on 05/05/21
27.68 -22.47%
on 06/14/21
+0.96 (+4.68%)
since 04/23/21
52-Week
19.20 +11.77%
on 05/05/21
57.46 -62.65%
on 11/25/20
-22.29 (-50.95%)
since 07/23/20

Most Recent Stories

More News
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

--- Pimavanserin met the secondary endpoint of significantly reducing trial discontinuation for any reason by 2.2 fold

ACAD : 21.46 (-3.46%)
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the U.S. financial markets. Acadia's...

ACAD : 21.46 (-3.46%)
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.

EXAS : 117.95 (-0.07%)
ACAD : 21.46 (-3.46%)
BPMC : 84.55 (-1.00%)
SAVA : 123.38 (-2.55%)
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

BMRN : 77.04 (-1.81%)
EXAS : 117.95 (-0.07%)
ACAD : 21.46 (-3.46%)
SYBX : 3.18 (-2.45%)
AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe

AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.

RGEN : 209.92 (+1.90%)
ACRX : 1.26 (-0.79%)
ZTS : 203.59 (+1.52%)
ACAD : 21.46 (-3.46%)
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer's Association International Conference 2021 (AAIC)

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer's Association International Conference(R)...

ACAD : 21.46 (-3.46%)
Bear of the Day: Inovio Pharmaceuticals (INO)

Is it too late to buy this coronavirus vaccine stock?

PFE : 41.68 (+0.51%)
MRNA : 348.83 (+7.84%)
INO : 8.20 (-5.09%)
ACAD : 21.46 (-3.46%)
Parkinson’s Dyskinesia Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2020-2025

Parkinson's disease is a long term neurodegenerative disorder which affects the dopamine producing neurons in specific areas of the brain known as substantia nigra. This disease belongs to a group of conditions...

ACAD : 21.46 (-3.46%)
GSK : 39.51 (+0.71%)
IPXL : 18.30 (unch)
MRK : 77.54 (+1.32%)
NWPHF : 2.8000 (+0.36%)
NVS : 91.57 (+0.54%)
TEVA : 8.81 (-1.01%)
VRX.TO : 30.80 (-3.33%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 21, 2021 - ACAD

New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

ACAD : 21.46 (-3.46%)
Today - Final Deadline for Investors With Losses Exceeding $100K to Actively Participate in ACADIA Pharmaceuticals Inc. (ACAD) Class Action: Bronstein, Gewirtz & Grossman, LLC

NEW YORK, NY / ACCESSWIRE / June 21, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ('ACADIA' or 'the Company')...

ACAD : 21.46 (-3.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

3rd Resistance Point 23.01
2nd Resistance Point 22.65
1st Resistance Point 22.05
Last Price 21.46
1st Support Level 21.09
2nd Support Level 20.73
3rd Support Level 20.13

See More

52-Week High 57.46
Fibonacci 61.8% 42.84
Fibonacci 50% 38.33
Fibonacci 38.2% 33.82
Last Price 21.46
52-Week Low 19.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar